Ken Griffin Evolus, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$10.45 - $13.76 $45,980 - $60,544	4,400 Added 47.31%	13,700 $148,000
Q1 2024 May 15, 2024	BUY	$9.99 - $14.91 $22,977 - $34,293	2,300 Added 32.86%	9,300 $130,000
Q4 2023 Feb 14, 2024	SELL	$7.6 - $10.53 $53,960 - $74,763	-7,100 Reduced 50.35%	7,000 $73,000
Q3 2023 Nov 14, 2023	BUY	$7.15 - $10.2 $48,620 - $69,360	6,800 Added 93.15%	14,100 $128,000
Q2 2023 Aug 14, 2023	BUY	$7.23 - $10.52 $20,967 - $30,508	2,900 Added 65.91%	7,300 $53,000
Q1 2023 May 15, 2023	SELL	$7.81 - $11.05 $50,765 - $71,825	-6,500 Reduced 59.63%	4,400 $37,000
Q4 2022 Feb 14, 2023	BUY	$6.52 - $8.95 $71,068 - $97,554	10,900 New	10,900 $81,000

163

49.1M

453K

14K

Ticker EOLS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 56,094,800
Market Cap $981M
Description
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.